发布求助
文献互助 智能选刊 最新文献

Medico Oncology最新文献

筛选
英文 中文
Translation of 15D questionnaire into Romanian language to study quality of life of cancer patients in Romania 将15D问卷翻译成罗马尼亚语，研究罗马尼亚癌症患者的生活质量
Medico Oncology Pub Date : 2021-05-25 DOI: 10.52701/MONC.2021.V2I1.16
A. Turcu-Știolica, M. Subtirelu
{"title":"Translation of 15D questionnaire into Romanian language to study quality of life of cancer patients in Romania","authors":"A. Turcu-Știolica, M. Subtirelu","doi":"10.52701/MONC.2021.V2I1.16","DOIUrl":"https://doi.org/10.52701/MONC.2021.V2I1.16","url":null,"abstract":"The 15D is a self-administered questionnaire for assessment of health-related quality of life, which contains 15 questions with 5 response options each. This research was aimed to translate the 15D questionnaire into Romanian to use for cancer patients and scientific community. The standard procedure of forward-backward translation was used in the translation procedure. The original questionnaire was given to two independent forward-translators (one English teacher and one experienced translator). The second step was the backward-translation with two English speakers who translated the first consensus version into English. The back translation was compared with the original version. The third step was the pilot-test on 15 patients and 10 healthy people. The patients’ obstacles in understanding and completing the questionnaires were reviewed and used to modify the questionnaires by the translation group. The final Romanian version of the 15D can be used for the next step of validation.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131148730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
IRON OXIDE MAGNETIC NANOPARTICLES AS DRUG DELIVERY SYSTEMS FOR BRAIN CANCER TREATMENT 氧化铁磁性纳米颗粒作为脑癌治疗的药物输送系统
Medico Oncology Pub Date : 2021-05-25 DOI: 10.52701/MONC.2021.V2I1.30
O. Purcaru, Alexandra Costachi, C. Cioc, A. Buteică, A. Dricu
{"title":"IRON OXIDE MAGNETIC NANOPARTICLES AS DRUG DELIVERY SYSTEMS FOR BRAIN CANCER TREATMENT","authors":"O. Purcaru, Alexandra Costachi, C. Cioc, A. Buteică, A. Dricu","doi":"10.52701/MONC.2021.V2I1.30","DOIUrl":"https://doi.org/10.52701/MONC.2021.V2I1.30","url":null,"abstract":"Nanotechnology offers a new horizon for cancer drug administration and systemic safety of oncological treatments. Compared with conventional pharmaceutical forms, nanoparticles (NPs) have many advantages such as larger surface, ability to adsorb and targeted delivery of different types of drugs, providing decreased side effects and a patient customed approach in cancer treatment. Due to their diverse chemical composition, NPs offer the possibility of developing innovative therapies, which may be also applied in glioblastoma treatment. Fe3O4 magnetic nanoparticles (MNPs) have been previously used in cancer treatment, as targeted drug delivery systems. Helianthin is an azo dye compound that we found to induce cell death in high grade glioma (HGG) cells. In this study, we analyzed the in vitro effect of MNPs loaded with Helianthin (HeMNPs) on a glioblastoma cell line (GB2B).","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133105498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
CLINICAL, IMAGING AND PATHOLOGICAL ASPECTS OF MAMMARY LYMPHOMAS SECONDARY TO MALIGNANT T- CELL CUTANEOUS LYMPHOMAS 恶性t细胞皮肤淋巴瘤继发乳腺淋巴瘤的临床、影像学及病理分析
Medico Oncology Pub Date : 2021-05-25 DOI: 10.52701/MONC.2021.V2I1.27
C. Lungulescu, G. Camen, Raluca-Elena Nica, V. Biciușcă, T. Sas
{"title":"CLINICAL, IMAGING AND PATHOLOGICAL ASPECTS OF MAMMARY LYMPHOMAS SECONDARY TO MALIGNANT T- CELL CUTANEOUS LYMPHOMAS","authors":"C. Lungulescu, G. Camen, Raluca-Elena Nica, V. Biciușcă, T. Sas","doi":"10.52701/MONC.2021.V2I1.27","DOIUrl":"https://doi.org/10.52701/MONC.2021.V2I1.27","url":null,"abstract":"Primary cutaneous lymphomas rank as the second most common clinical form of extranodal non-Hogdkin malignant lymphomas. Among non-Hodgkin malignant skin T-cell lymphomas, Mycosis Fungoides (MF) is the most frequent clinical occurence. The MF lymphoma originates in skin-homing helper T-cells, which express the CD4 + marker, showing chronic evolution, with recurrent lesions. In advanced stages, patients with Mycosis Fungoides may experience severe/extensive skin lesions or extracutaneous localizations of the disease. The secondary breast lymphoma is more common in non-Hodgkin malignant lymphoma than in Hodgkin lymphoma. Among the mammographic characteristics of breast lymphoma we mention: oval or round tumor mass, with well-defined or indistinct margins, absence of intratumoral calcifications, presence of intramammary lymph nodes, supra-adjacent skin thickening and lymphedema that causes diffuse increase in breast density. The ultrasound features of breast lymphoma run as follows: it is oval or round in shape, with well-defined or indistinct margins, which in Doppler ultrasound are identified as hypervascularized masses. The description of the imaging features of mammary lymphomas secondary to cutaneous T-cell lymphomas is required before performing the breast core-needle biopsy.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"112 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127560793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Serum Ferritin Levels in Brain Tumors 脑肿瘤患者血清铁蛋白水平的评价
Medico Oncology Pub Date : 2021-05-25 DOI: 10.52701/MONC.2021.V2I1.18
Oana Alexandru, L. Ene
{"title":"Evaluation of Serum Ferritin Levels in Brain Tumors","authors":"Oana Alexandru, L. Ene","doi":"10.52701/MONC.2021.V2I1.18","DOIUrl":"https://doi.org/10.52701/MONC.2021.V2I1.18","url":null,"abstract":"Currently, brain tumors are diagnosed based on clinical suspicion and neuroimaging results. Histological analysis is the only method that certifies the diagnosis and establishes the prognosis. A number of studies suggest that perturbed iron metabolism and increased ferritin levels are part of the changes associated with tumorigenesis. Our study’s aim is to evaluate serum ferritin levels in a series of patients and establish if this protein could play a role in brain cancer diagnosis and prognosis. Our lot is comprised of 267 patients with various types of brain tumors. We registered higher mean ferritin levels when compared to the general population. According to tumor histology, higher levels were found in cerebral metastases patients, and the differences were statistically significant. According to tumor grading, we found higher ferritin levels in grade II tumors, with statistically significant differences when compared to grade I and grade IV tumors. It remains an open question if high ferritin levels are a hallmark for cerebral metastases or just an expression of systemic dissemination. Also, a possible role for ferritin as a biomarker in grade II brain tumors may be established by further studies.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116349785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THE EFFECT OF BETA - ARRESTIN 1 TRANSFECTION ON PROLIFERATION AND TEMOZOLOMIDE TREATMENT RESPONSE IN HGG CELLS 转染β -抑制素1对HGG细胞增殖和替莫唑胺治疗反应的影响
Medico Oncology Pub Date : 2021-05-18 DOI: 10.52701/MONC.2020.V1I1.5
Cristina Horescu, S. Artene
{"title":"THE EFFECT OF BETA - ARRESTIN 1 TRANSFECTION ON PROLIFERATION AND TEMOZOLOMIDE TREATMENT RESPONSE IN HGG CELLS","authors":"Cristina Horescu, S. Artene","doi":"10.52701/MONC.2020.V1I1.5","DOIUrl":"https://doi.org/10.52701/MONC.2020.V1I1.5","url":null,"abstract":"While several studies have indicated a major role of the ?-arrestin family in the development of several types of cancer, little to no information is available on its influence in malignant gliomas. \u0000In our study we transfected an established high-grade glioma cell line, 11 HGG with a ?-1 arrestin plasmid in order to observe how ?-1 overexpression influences proliferation and response to standard of care treatment. After 24h, the transfected cells presented a drop in proliferation when compared to untransfected cells. In terms of treatment response, transfected cells presented a markedly elevated cytotoxic effect when compared to untransfected cells. However, after 48h and 72h transfected cells presented only a minor increase in proliferation while treatments responses to TMZ were modestly influenced by ?-1 arrestin overexpression.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"143 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134488021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
BIOBANKS. ASSOCIATED RISKS AND BENEFITS 起生物。相关的风险和收益
Medico Oncology Pub Date : 2021-05-18 DOI: 10.52701/MONC.2020.V1I1.11
Edmond Barcan, S. Artene, A. Dricu
{"title":"BIOBANKS. ASSOCIATED RISKS AND BENEFITS","authors":"Edmond Barcan, S. Artene, A. Dricu","doi":"10.52701/MONC.2020.V1I1.11","DOIUrl":"https://doi.org/10.52701/MONC.2020.V1I1.11","url":null,"abstract":"Biobanks are repositories of human organic material, that have an important role in the clinic. The World Health Organization (WHO) and the Global Health Ethics Unit have a great contribution considering the ideology of a well-functioning biobank. At the European Union, the functioning of biobanks is strictly regulated and research is being sustained by programs financed at a community level. The administration of biobanks brings both advantages and risks socially. To prevent these, international standards have been implemented for biobanks. In the research domain but also in the public health domain, an analysis in accordance with the legal framework must be considered in order to preserve the well-functioning of biobanks.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"202 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115023370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RECENT PROGRESS IN OVARIAN CANCER THERAPY 卵巢癌治疗的最新进展
Medico Oncology Pub Date : 2021-05-18 DOI: 10.52701/MONC.2020.V1I1.10
Adeline-Georgiana Staicu, Cristina Horescu, S. Tudorache
{"title":"RECENT PROGRESS IN OVARIAN CANCER THERAPY","authors":"Adeline-Georgiana Staicu, Cristina Horescu, S. Tudorache","doi":"10.52701/MONC.2020.V1I1.10","DOIUrl":"https://doi.org/10.52701/MONC.2020.V1I1.10","url":null,"abstract":"Ovarian cancer (OC) represents the leading cause of gynecological cancer deaths in women. It has a high variety of histological origins, molecular pathways and genetic mutations (BRCA1 and BRCA2 somatic/germinal mutations, Lynch genes, RADS1C, RADS1D etc.) that play a key role in treatment response and prognosis (for example, clear cell carcinoma is less responsive to standard therapy). An important percentage of patients (80%) are diagnosed with metastatic disease, due to the lack of specific symptomatology and screening techniques leading to a dismal evolution. Standard treatment did not change drastically in decades consisting, nowadays, of cytoreductive surgery (debulking) and chemotherapy (a platinum-based agent, usually carboplatin and a taxane). Most patients experience complete response, but within a period of time, relapses occur and the cancerous cells may become platinum-resistant. This article depicts key clinical trials for many pharmacological agents including anti-angiogenesis drugs (bevacizumab, aflibercept, trebananib, pazopanib, sorafenib etc.), PARP-inhibitors (olaparib, niraparib), DNMT inhibitors (decitabine, azacytidine), various TKIs, DNA vaccines, oncolytic virus therapies and other agents.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123493270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
THE BENEFITS VS POTENTIAL SIDE EFFECTS OF POSTCHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA 肝细胞癌化疗后栓塞治疗的益处与潜在副作用
Medico Oncology Pub Date : 2021-05-18 DOI: 10.52701/MONC.2020.V1I1.7
C. Siloşi, M. Boldeanu, A. Andritoiu, M. Cojocaru, L. Boldeanu, C. Avramescu, I. Siloși
{"title":"THE BENEFITS VS POTENTIAL SIDE EFFECTS OF POSTCHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA","authors":"C. Siloşi, M. Boldeanu, A. Andritoiu, M. Cojocaru, L. Boldeanu, C. Avramescu, I. Siloși","doi":"10.52701/MONC.2020.V1I1.7","DOIUrl":"https://doi.org/10.52701/MONC.2020.V1I1.7","url":null,"abstract":"It is known that, among chronic liver diseases, the most common cause of morbidity and/or mortality is hepatocellular carcinoma. Due to the fact that most patients are diagnosed with advanced disease, surgical resection is no longer possible. These patients constitute the ideal group for transarterial chemoembolization, which consists of the local infusion of a mixture of chemotherapeutic agents, which will cause the suppression of blood supply of the cancerous lesions, the induction of ischemia, followed by the necrosis of the tumor tissue, with a considerable improvement in the survival rate.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123667013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PLANT-DERIVED CHEMOTHERAPEUTICS DRUGS FOR CANCER CHEMOTHERAPY 用于癌症化疗的植物性化疗药物
Medico Oncology Pub Date : 2020-09-02 DOI: 10.52701/MONC.2020.V1I1.8
Alexandra Dragoi, Oana Alexandru
{"title":"PLANT-DERIVED CHEMOTHERAPEUTICS DRUGS FOR CANCER CHEMOTHERAPY","authors":"Alexandra Dragoi, Oana Alexandru","doi":"10.52701/MONC.2020.V1I1.8","DOIUrl":"https://doi.org/10.52701/MONC.2020.V1I1.8","url":null,"abstract":"Cancer chemotherapeutic drugs acts in different manner to kill malignant cells. Most of the anticancer drugs available in clinical practice to treat cancer patients, are natural products including whole plant extract, crude plant extracts, isolated constituents, plant –based drug formulations etc. These natural compounds have been a basis for the development of several drugs against cancer. Agents such as topotecan, taxol, vinca alkaloids (vincristine, vinblastine, vinorelbine and vindesine), are important anticancer agents in widespread clinical use. Other agents, such as combretastatin, flavopiridol, betulinic acid were shown to have anti-tumor effects in both in vitro and in vivo experiments. \u0000In this review, we aim to make a brief description of classical plant-derived chemotherapeutics drugs and also to highlight the importance of these natural compounds in the development of new potential drugs in cancer treatment.","PeriodicalId":299951,"journal":{"name":"Medico Oncology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133091294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信